Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
View Top Employees from Medivir Ab| Website | http://www.medivir.se |
| Ticker | MVIRB |
| Revenue | $76 million |
| Employees | 24 (0 on RocketReach) |
| Founded | 1988 |
| Address | Lunastigen 7, Huddinge, Stockholm 141 22, SE |
| Phone | +46 8 546 831 00 |
| Fax | (468) 407-6439 |
| Industry | Manufacturing General, Pharmaceutical, Manufacturing, Health Care |
| Competitors | Heron Therapeutics, Inc., Pascal Biosciences Inc., Synergy Pharmaceuticals Inc., Therapeutic Products Inc, Welichem Biotech Inc. |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Medivir Ab employee's phone or email?
Medivir Ab Questions
The Medivir Ab annual revenue was $76 million in 2024.
Medivir Ab is based in Huddinge, Stockholm.
The NAICS codes for Medivir Ab are [325, 3254, 32, 32541].
The SIC codes for Medivir Ab are [283, 28].
Related Companies
